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Background-—We aimed to assess the associations and predictive powers between the soluble receptors for tumor necrosis factor
(TNF)-a (TNFR1 and TNFR2) and cardiovascular outcomes in patients with stable coronary heart disease.
Methods and Results-—CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) is
a randomized clinical trial comparing clarithromycin with placebo in patients with stable coronary heart disease. The primary
outcome was a composite of nonfatal acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, and all-cause
mortality. Patients were followed up for 10 years; discovery sample, those assigned placebo (1204 events in n=1998); and
replication sample, those assigned clarithromycin (1220 events in n=1979). We used Cox regression adjusted for C-reactive
protein level, established cardiovascular risk factors, kidney function, and cardiovascular drugs. After adjustments, higher serum
levels of TNFR1 and TNFR2 were associated with the composite outcome in the discovery sample (hazard ratio per SD increase,
1.13; 95% conﬁdence interval, 1.05–1.22; P=0.001 for TNFR1; hazard ratio, 1.16; 95% conﬁdence interval, 1.08–1.24; P<0.001 for
TNFR2). The associations were similar in the replication sample. The associations with the composite outcome were mainly driven
by acute myocardial infarction, cardiovascular mortality, and noncardiovascular mortality. The addition of TNFR1 and TNFR2 to
established cardiovascular risk factors improved prediction only modestly (<1%).
Conclusions-—Increased concentrations of circulating TNFR1 and TNFR2 were associated with increased risks of cardiovascular
events and mortality in patients with stable coronary heart disease. Yet, the utility of measuring TNFR1 and TNFR2 to improve risk
prediction in these patients appears limited.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT00121550. ( J Am Heart Assoc. 2018;7:
e008299. DOI: 10.1161/JAHA.117.008299.)
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T he soluble receptors for tumor necrosis factor (TNF)-a(TNFR1 and TNFR2) have important roles in cellular
stress response and inﬂammatory cascades, both important
pathways for the development of cardiovascular disease.1,2
Higher levels of circulating endogenous TNFR1 and TNFR2 have
been associated with increased risk of mortality and adverse
cardiovascular outcomes in patients and in the general
population after accounting for known inﬂammatory markers,
such as C-reactive protein (CRP).3–10 To our knowledge, there is
no previous study on the association between circulating
TNFR1 and TNFR2 and the risk of cardiovascular events and
death in patients with stable coronary heart disease. Clarifying
these associations and the relationship to established risk
markers could highlight potential causal mechanisms and
improve risk prediction in this large group of high-risk people.
In the present study, we aimed to assess the association
between serum levels of TNFR1 and TNFR2 with fatal and
nonfatal cardiovascular events and all-cause mortality using
the 10-year follow-up data in the CLARICOR (Effect of
Clarithromycin on Mortality and Morbidity in Patients With
Ischemic Heart Disease11) trial. The CLARICOR trial compared
clarithromycin with placebo in patients with stable heart
disease and found short-term clarithromycin to be associated
with higher mortality.12
Methods
Trial Design and Participants
The anonymized data, analytic methods, and study materials
will be made available to other researchers for purposes of
reproducing the results or replicating the procedure. The data
will be shared at ZENODO (http://zenodo.org), identiﬁable by
the DOI number.
The CLARICOR trial is an investigator-initiated, randomized,
placebo-controlled, blinded, multicenter, superiority trial that
involved 4372 Danish patients with stable coronary heart
disease who were randomly assigned by a central algorithm in
a 1:1 ratio to clarithromycin versus placebo. The trial was
inspired by the hypothesis that coronary vulnerability could be
attributable to bacterial colonization of the arterial walls.12–15
The CLARICOR trial complies with the Declaration of Helsinki
and has been approved by the local ethics committees and
regulatory authorities (Regional Ethics Committee KF 01-076/
99 and HB 2009/015; the Danish Data Protection Agency
1999-1200-174 and 2012-41-0757; and the Danish Medici-
nes Agency 2612–975). All residents of Copenhagen, Den-
mark, with a hospital diagnosis of myocardial infarction or
angina pectoris (International Statistical Classiﬁcation of
Diseases [ICD] codes I20.9–I21.9) between 1993 and 1999,
were identiﬁed and, if alive, invited by mail in late 1999 to
participate in the trial. After providing informed consent,
eligible participants with stable coronary heart disease were
randomized to a 2-week regimen of either clarithromycin,
500 mg (Klacid Uno), administered orally once daily, or
placebo. We excluded participants with short-term events or
major chronic disease at the time of randomization, those
who had experienced acute myocardial infarction (AMI) or
angina pectoris episode during the previous 3 months, and
those who had also not been subjected to percutaneous
transluminal coronary angioplasty and coronary bypass
surgery during the previous 6 months. Participants were
followed up for, on average, 10 years from the end of
treatment in April 2000 until December 31, 2009, through
Danish population registers. Comorbidities and treatment
details were obtained from hospital records supported by data
from the Register of Causes of Death and the Centrale
Person-Register (Table S1). Smoking status was obtained
through a questionnaire and coded as never, former, or
current smoker.
In the present study, we used the placebo group of the
CLARICOR trial as discovery sample and the clarithromycin
group as replication sample, although possible distortion of
associations by the active intervention cannot be excluded in
the latter group.16 We excluded participants with missing data
in any of the variables, leaving n=1998 participants in the
discovery group and n=1979 participants in the replication
group.
Laboratory Analyses
Laboratory analyses were performed on Mindray BS380
(Mindray, Shenzhen, China) with reagents from Abbott
Laboratories (Abbott Park, IL), according to the manufac-
turer’s instructions (Table S1). Estimated glomerular ﬁltration
rate was estimated using the creatinine-based Chronic Kidney
Clinical Perspective
What Is New?
• Elevated endogenous levels of the soluble receptors for
tumor necrosis factor (TNF)-a (TNFR1 and TNFR2) were
associated with cardiovascular events and mortality over
10 years of follow-up in patients with stable coronary heart
disease at baseline.
What Are the Clinical Implications?
• The utility of measuring TNFR1 and TNFR2 to improve risk
prediction in patients with stable coronary heart disease
appears limited, and it remains to be shown if the risk
associated with circulating levels of TNFR1 and TNFR2 can
be lowered by statins, anti-TNF therapy, other pharmaceu-
tical drugs, or lifestyle interventions.
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Disease Epidemiology Collaboration formula.17 Blood samples
were obtained at baseline and immediately frozen and stored
at 70°C. Serum levels of endogenous TNFR1 and TNFR2
were analyzed by ELISA kits DY225 and DY726 by R&D
Systems (Minneapolis, MN). The assays had a total coefﬁcient
of variation of 6% (coefﬁcient of variation data obtained from
manufacturer). Laboratory technicians were blinded to par-
ticipant assignment.
Public Register–Based Outcomes
For every participant, the unique 10-digit Danish personal
identity number was linked to the National Patient Register,
the Danish Central Civil Register, and the National Register of
Causes of Death. For each recorded main diagnosis and for
each underlying cause of death, we classiﬁed the outcome into
a priority list of disjoint and exhaustive categories: AMI (ICD
codes I21.0–I23.9), unstable angina pectoris (ICD codes I20.0
and I24.8–I24.9), cerebrovascular disease (ICD codes I60.0–
I64.9 and G45.0–G46.8), peripheral vascular disease (ICD
codes I70.2–I70.9), other cardiovascular diseases (ICD codes
I00.0–I99.9, unless already covered), and noncardiovascular
disease (ICD codes A00.0–T98.3, unless already covered).18
We also constructed a composite outcome composed of AMI,
unstable angina pectoris, cerebrovascular disease, or all-
cause death during follow-up.
Statistical Analysis
Spearman0s correlation coefﬁcient was used to determine the
crude correlation between the TNFRs and other biomarkers.
For all subsequent analyses, TNFR1 and TNFR2 levels were
natural logarithm transformed to fulﬁl the linearity assump-
tion. Log transformation was also applied to CRP and
apolipoprotein B. The following multivariable Cox proportional
hazards regression models were conducted to study the
association between either TNFR and outcomes in the
following models:
Model A was adjusted for sex and CRP, to show that the
TNFRs provide predictive information beyond the most
commonly used inﬂammatory marker in clinical practice.
Model B was adjusted for factors in model A and
established cardiovascular risk factors (hypertension, dia-
betes mellitus, smoking, apolipoprotein A1, and
apolipoprotein B), to determine if either TNFR provides
information independent of risk factors assessed in clinical
practice.19,20
Model C was adjusted for factors in model B and estimated
glomerular ﬁltration rate, because the TNFRs have been
shown previously to be associated with both kidney
function and incident chronic kidney disease,21,22 to rule
out that the TNFRs mirror more than kidney function.
Model D was adjusted for established risk factors,
comorbidities and cardiovascular pharmacotherapies, and
standard biochemical predictors, as shown in Table S1.
Model D was used as the standard model for primary
analysis, as predeﬁned in the study protocol.16
The proportional hazards assumption for Cox regression was
violated for age for the outcomes all-cause death and the
composite outcome (ie, age at entry; Bonferroni adjusted
P<0.00056 for the composite outcome, and P<0.0044 for all-
cause mortality). Accordingly, we choose to omit age from all
Coxmodels for those 2 outcomes. To provide additional insights
into the potential inﬂuence of age on the association between
TNFR1 and TNFR2 and these outcomes, we also conducted
multivariable logistic regression and accelerated failure time
models (including age as a covariate because the proportional
hazard assumption is not a requisite for these analyses).
Improvement in prediction, relative to that obtained when
standard predictors (available from routinely available clinical
information model D [Table S1]) were used, was calculated in
accordance with the published statistical analysis plan.16
We used curves (penalized splines) to see the potential
nonlinearity of the associations between either TNFR and the
outcome, where the hazard ratio was plotted against the
circulating TNFR concentration.
An extension to Stata involving Laplace regression was
provided by Professor M. Bottai at Karolinska Institutet
(Huddinge, Sweden)23 and was used to calculate the differ-
ence in time for every SD increment of TNFR1 and TNFR2 until
50% of the patients in the respective cohorts were diagnosed
with the composite end point. In the Laplace regression
calculations we conducted, a negative survival time ﬁgure
represents a reduction in median time to event for every SD
increment in TNFR1 and TNFR2. Analyses were conducted in
STATA, version 14.2 (StataCorp, College Station, TX).
Results
Baseline Characteristics
Baseline characteristics of the discovery and replication
samples are presented in Table 1.
Spearman Correlations at Baseline
TNFR1 and TNFR2 were highly correlated; Spearman0s
correlation was 0.70 in the discovery cohort and 0.67 in the
replication cohort. The Spearman0s correlations between
TNFR1 and the following biomarkers in the discovery/
replication sample were as follows: CRP, 0.28/0.30; crea-
tinine, 0.38/0.37; apolipoprotein B, 0.05/0.09; apolipopro-
tein A1, 0.07/0.11 (P≤0.005 when correlation ≥0.06). The
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corresponding correlations for TNFR2 were as follows: CRP,
0.29/0.35; creatinine, 0.39/0.37; apolipoprotein B, 0.06/
0.09; and apolipoprotein A1, 0.08/0.12. The distributions
of TNFR1 and TNFR2 in the discovery and replication
populations are shown as Figures S1 and S2.
Follow-Up Results at 10 Years
The number of events for all outcomes and the incidence
rates (number of events per 100 person-years) are shown for
both groups of participants in Table 2. The mean follow-up
until censoring or death was 6.5 years in the discovery
sample and 6.4 years in the replication sample for the
composite outcome. The maximum follow-up was 10.2 years.
The association between TNFR1 and all outcomes is shown
in Table 3 and Figure 1 (composite outcome), and the
corresponding associations for TNFR2 are shown in Table 4
and Figure 2. Both receptors were signiﬁcantly associated
with the composite outcome, as seen in the spline curves and
in models adjusted for inﬂammation and established cardio-
vascular risk factors (both in the discovery and replication
sample; P<0.001 for both). Associations persisted after
additional adjustments for kidney function and cardiovascular
pharmacotherapies. These associations were similar in
Table 1. Baseline Characteristics in the Discovery (Placebo)
and Replication (Clarithromycin) Cohorts
Variable
Discovery
Cohort
Replication
Cohort
No. of participants 1998 1979
Female sex 624 (31) 603 (30)
Age, y 6510 6510
TNFR1, pg/mL 1770797 1776836
TNFR2, pg/mL 53862011 54162099
CRP, mg/L 5.257.7 5.769.3
Apolipoprotein A1, mg/dL 1.700.34 1.700.36
Apolipoprotein B, mg/dL 1.210.32 1.210.33
Diabetes mellitus 300 (15) 301 (15)
Hypertension 805 (40) 790 (40)
eGFR, mL/min 76.320 76.519
Smoking status
Never 395 (20) 338 (17)
Former 925 (46) 906 (46)
Current 678 (34) 735 (37)
Previous myocardial infarction 636 (32) 640 (32)
Statin treatment 822 (41) 814 (41)
Aspirin treatment 1764 (88) 1737 (88)
b-Blocker treatment 619 (31) 591 (30)
Calcium antagonist treatment 702 (35) 681 (34)
ACE inhibitor treatment 523 (26) 553 (28)
Long-acting nitrate treatment 412 (21) 411 (21)
Diuretics 691 (37) 702 (35)
Digoxin treatment 117 (7) 140 (7)
Antiarrhythmic treatment 42 (2) 46 (2)
Data are meanSD for continuous variables and number (percentage) for categorical
variables. ACE indicates angiotensin-converting enzyme; CRP, C-reactive protein; eGFR,
estimated glomerular ﬁltration rate; and TNFR1/TNFR2, soluble receptors for tumor
necrosis factor-a.
Table 2. Number of Outcomes, Numbers at Risk, and
Incidence Rates With 95% CIs for the Studied Outcomes
Outcomes
Discovery
Cohort
Replication
Cohort
Composite outcome
NE, n (%) 1204 (60) 1220 (62)
IR per 100 y 9.23 9.67
95% CI 8.72–9.76 9.15–10.23
Acute myocardial infarction
NE, n (%) 446 (22) 422 (21)
IR per 100 y 2.97 2.90
95% CI 2.71–3.26 2.63–3.19
Unstable angina pectoris
NE, n (%) 356 (18)* 356 (18)*
IR per 100 y 2.40 2.50
95% CI 2.16–2.66 2.25–2.77
Stroke
NE, n (%) 298 (15) 324 (16)
IR per 100 y 1.91 2.18
95% CI 1.71–2.14 1.96–2.43
Cardiovascular mortality
NE, n (%) 382 (19) 348 (17)
IR per 100 y 2.39 2.10
95% CI 2.15–2.64 1.88–2.32
Noncardiovascular mortality
NE, n (%) 390 406
IR per 100 y 2.34 2.54
95% CI 2.12–2.59 2.30–2.80
All-cause mortality
NE, n (%) 738 (37) 788 (40)
IR per 100 y 4.44 4.92
95% CI 4.13–4.77 4.59–5.28
CI indicates conﬁdence interval; IR, incidence rate per 100 person-years of follow-up,
estimated rates (per 100) and lower/upper bounds of 95% CIs; and NE, number of events
(percentage of participants at risk).
*The number of events was exactly the same in the placebo and the clarithromycin arms.
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logistic regression analyses and accelerated time failure
models that also included age as a covariate (Tables S2 and
S3).
Higher levels of both the receptors were also signiﬁcantly
associated with a higher risk of myocardial infarction, but for
TNFR2, the association was attenuated and no longer
signiﬁcant in the fully adjusted models. Stroke and unstable
angina pectoris were not predicted by levels of TNFR1 in any
model or sample. In contrast, TNFR2 was signiﬁcantly
associated with stroke in the clarithromycin group, an
intergroup discrepancy that is itself weakly signiﬁcant. Both
receptors were associated with noncardiovascular mortality
and total mortality in all models tested in both samples
(P<0.001). TNFR1 was also strongly associated with cardio-
vascular mortality in all models (P<0.001), whereas the
association between TNFR2 levels and cardiovascular mortal-
ity was attenuated in models adjusted for kidney function and
cardiovascular pharmacotherapies and no longer signiﬁcant in
the discovery sample.
There was no signiﬁcant interaction between TNFR1 or
TNFR2 and a previous diagnosis of myocardial infarction or
angina pectoris at baseline for the association with the
Table 3. Hazard Factors Associated With 1 (Patient-to-Patient) SD TNFR1 Increment
Variable
Discovery Cohort Replication Cohort
Model A Model B Model C Model D Model A Model B Model C Model D
Composite outcome*
Hazard ratio 1.32 1.30 1.15 1.13 1.34 1.33 1.18 1.16
95% CI 1.24–1.40 1.23–1.38 1.07–1.23 1.05–1.22 1.27–1.42 1.25–1.41 1.10–1.26 1.08–1.24
P value <0.001 <0.001 <0.001 0.001 <0.001 <0.001 <0.001 <0.001
Acute myocardial infarction
Hazard ratio 1.30 1.25 1.19 1.19 1.26 1.20 1.18 1.16
95% CI 1.17–1.44 1.13–1.39 1.06–1.34 1.06–1.34 1.13–1.39 1.08–1.34 1.05–1.34 1.03–1.31
P value <0.001 <0.001 0.003 0.004 <0.001 0.001 0.006 0.017
Unstable angina pectoris
Hazard ratio 1.06 1.04 1.03 1.01 1.14 1.11 1.11 1.10
95% CI 0.95–1.20 0.92–1.16 0.91–1.17 0.88–1.15 1.01–1.27 0.99–1.25 0.98–1.26 0.97–1.25
P value 0.30 0.56 0.64 0.93 0.03 0.071 0.08 0.14
Stroke
Hazard ratio 1.05 1.02 0.99 0.96 1.15 1.10 1.06 1.05
95% CI 0.93–1.20 0.90–1.16 0.86–1.15 0.83–1.11 1.02–1.30 0.97–1.24 0.93–1.22 0.92–1.20
P value 0.43 0.72 0.93 0.56 0.024 0.14 0.37 0.48
Cardiovascular mortality
Hazard ratio 1.34 1.30 1.17 1.14 1.33 1.27 1.22 1.16
95% CI 1.19–1.50 1.15–1.46 1.03–1.35 0.99–1.31 1.19–1.48 1.14–1.43 1.07–1.38 1.02–1.31
P value <0.001 <0.001 0.018 0.065 <0.001 <0.001 0.002 0.024
Noncardiovascular mortality
Hazard ratio 1.43 1.41 1.43 1.41 1.35 1.33 1.31 1.29
95% CI 1.28–1.60 1.26–1.58 1.26–1.63 1.25–1.63 1.22–1.50 1.19–1.48 1.16–1.48 1.14–1.46
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
All-cause mortality*
Hazard ratio 1.66 1.64 1.33 1.31 1.53 1.53 1.25 1.22
95% CI 1.54–1.78 1.53–1.77 1.21–1.45 1.19–1.43 1.43–1.64 1.43–1.64 1.16–1.36 1.13–1.33
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Model A was adjusted for age, sex, and C-reactive protein. Model B was adjusted for factors in model A and established cardiovascular risk factors (hypertension, diabetes mellitus,
smoking, apolipoprotein A1, and log[apolipoprotein B]). Model C was adjusted for factors in model B and estimated glomerular ﬁltration rate. Model D was adjusted for established risk
factors and comorbidities, standard biochemical predictors, and treatments, as shown in Table S1. CI indicates conﬁdence interval; and TNFR1, the soluble receptor for tumor necrosis
factor-a 1.
*Proportional hazards assumption was violated for age; all models in this row are shown without adjustments for age.
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combined outcome (TNFR1, P=0.17; TNFR2, P=0.13; data not
shown in tables).
Prediction Improvement
The number and percentage of correct predictions obtained
for the composite outcome and all-cause mortality when
TNFR1 and TNFR2 are added to standard predictors are
shown in Table 5. Only small improvements were seen (<1%).
Difference in Median Survival Time for the
Composite Outcome
In Laplace regression in the placebo group, 1-SD higher levels
of log TNFR1 were associated with 0.93 (95% conﬁdence
interval, 0.48–1.37) years earlier occurrence of the composite
outcome in a model adjusted for age, sex, CRP, and estimated
glomerular ﬁltration rate (P<0.001). The corresponding num-
ber in the clarithromycin group was 1.21 (95% conﬁdence
interval, 0.86–1.55) years (P<0.001). An SD increment in
TNFR2 was associated with 0.89 (95% conﬁdence interval,
0.51–1.28) years reduction of median time in the placebo
group and 1.06 (95% conﬁdence interval, 0.78–1.34) years
reduction of median time in the clarithromycin group.
Discussion
Main Findings
Elevated endogenous levels of TNFR1 and TNFR2 were associ-
ated with cardiovascular events and mortality over 10 years of
follow-up in patients with stable coronary heart disease at
baseline. The median time until cardiovascular events occurred
was 1 year earlier for every SD increase in serum concentra-
tion of either receptor. These associations were independent of
inﬂammation (CRP), kidney function, established cardiovascular
risk factors, and cardiovascular pharmacotherapies. Among
subgroups of outcomes, the strongest associations were found
between elevated levels of TNFRs and AMI, cardiovascular
mortality, and noncardiovascular mortality. These associations
were found in both the placebo group and clarithromycin-
exposed group of the study. However, only small improvements
in prediction of events were seen when TNFR1 and TNFR2 were
added to a model with standard predictors. The CLARICOR trial
results did not seem to affect the association between TNFR1
and TNFR2 and any of the outcomes.
Strengths and Limitations
The present study has several strengths, including the large
study sample with detailed characterization of the participants,
the longitudinal study design, the 10 years of follow-up, and
the replication of ﬁndings in the clarithromycin group of the
study. To our knowledge, the present study is the only cohort
study on associations between circulating endogenous levels
of TNFR1 and TNFR2 in patients with stable coronary heart
disease. The national registers of Denmark are known to be of
high completeness and accuracy24; however, a small number
of events may have been missed because of hospitalization
abroad. More important, the results apply to stable coronary
disease as ascertained at baseline interview rather than
prompted by acute symptoms or made during recovery from a
A B
Figure 1. Spline curve of the association between the soluble receptor for tumor necrosis factor-a 1
(sTNFR1) and the composite outcome as hazard ratio with 95% conﬁdence intervals (dotted lines) in the
discovery cohort (A) and the replication cohort (B). The mean level of sTNFR1 was 1776836 pg/mL in the
discovery cohort and 1770797 pg/mL in the replication cohort.
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major event. Limitations include the unknown generalizability
to other ethnic groups and to those unlikely to volunteer. In
the replication sample, distortion by the active intervention
with clarithromycin cannot be excluded, although associations
were broadly similar to those in the placebo group.
Possible Mechanisms for the Observed
Associations
TNF-a, TNFR1, and TNFR2 are activated in numerous patho-
logical processes and basic cellular mechanisms,1,2 making
the causal network behind our observational ﬁndings chal-
lenging to elaborate on. Several mechanisms may explain the
association between a long-term state of low-level inﬂamma-
tion, increased TNFR1 and TNFR2 levels, and cardiovascular
outcomes and mortality.
First, several heart-speciﬁc associations have been
reported. Higher levels of both TNFR1 and TNFR2 have
been associated with increased infarct size and left ventric-
ular dysfunction in patients with AMI and ST-segment
elevation.25 TNFR1 has been shown to be persistently
elevated in patients with coronary artery disease,26 but the
Table 4. Hazard Factors Associated With 1 (Patient-to-Patient) SD TNFR2 Increment
Variable
Discovery Cohort Replication Cohort
Model A Model B Model C Model D Model A Model B Model C Model D
Composite end point*
Hazard ratio 1.33 1.31 1.15 1.16 1.37 1.36 1.20 1.16
95% CI 1.25–1.41 1.23–1.39 1.08–1.24 1.08–1.24 1.29–1.45 1.28–1.44 1.12–1.29 1.08–1.25
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Acute myocardial infarction
Hazard ratio 1.29 1.24 1.18 1.19 1.17 1.12 1.09 1.06
95% CI 1.16–1.43 1.11–1.37 1.05–1.32 1.06–1.34 1.05–1.31 1.00–1.26 0.96–1.24 0.93–1.20
P value <0.001 <0.001 0.007 0.004 0.005 0.042 0.164 0.40
Unstable angina pectoris
Hazard ratio 1.07 1.04 1.04 1.05 1.06 1.03 1.01 0.99
95% CI 0.95–1.21 0.92–1.18 0.91–1.19 0.92–1.20 0.94–1.19 0.91–1.17 0.88–1.16 0.86–1.13
P value 0.24 0.50 0.56 0.48 0.37 0.64 0.87 0.85
Stroke
Hazard ratio 1.04 1.01 0.98 0.95 1.25 1.20 1.19 1.17
95% CI 0.91–1.19 0.88–1.15 0.84–1.13 0.82–1.10 1.11–1.42 1.06–1.37 1.04–1.37 1.02–1.35
P value 0.53 0.88 0.75 0.51 <0.001 0.004 0.014 0.026
Cardiovascular mortality
Hazard ratio 1.34 1.29 1.17 1.19 1.27 1.23 1.16 1.10
95% CI 1.19–1.51 1.15–1.45 1.02–1.34 1.04–1.37 1.13–1.42 1.09–1.38 1.02–1.32 0.96–1.25
P value <0.001 <0.001 0.024 0.012 <0.001 0.001 0.026 0.164
Noncardiovascular mortality
Hazard ratio 1.47 1.44 1.47 1.47 1.37 1.36 1.35 1.31
95% CI 1.32–1.64 1.29–1.61 1.30–1.67 1.30–1.68 1.23–1.53 1.21–1.51 1.19–1.53 1.16–1.49
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
All-cause mortality*
Hazard ratio 1.69 1.68 1.35 1.36 1.59 1.59 1.31 1.24
95% CI 1.57–1.82 1.56–1.81 1.24–1.48 1.24–1.49 1.48–1.71 1.48–1.71 1.19–1.43 1.13–1.35
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Model A was adjusted for age, sex, and C-reactive protein. Model B was adjusted for factors in model A and established cardiovascular risk factors (hypertension, diabetes mellitus,
smoking, apolipoprotein A1, and apolipoprotein B). Model C was adjusted for factors in model B and estimated glomerular ﬁltration rate. Model D was adjusted for established risk factors
and comorbidities, standard biochemical predictors, and treatments, as shown in Table S1. CI indicates conﬁdence interval; and TNFR2, soluble receptor for tumor necrosis factor-a 2.
*Proportional hazards assumption was violated for age; all models in this row are shown without adjustments for age.
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levels seem to be normalized by revascularization of the
heart.
Second, the association between TNFR1 and TNFR2 and
AMI and cardiovascular mortality might be explained by their
atherosclerotic effects as markers of a systemic inﬂammatory
state that is often present in patients with coronary heart
disease.10,27 Inﬂammation may initiate the reaction leading to
an atherosclerotic lesion and may also trigger plaque rupture,
the ﬁnal event behind most thrombotic and atherosclerotic
events.28 TNFR1 and TNFR2 were correlated with CRP
(q0.30, P<0.001), indicating that they portray partly the
same aspects in our cohorts. Yet, all Cox regression models
we reported were adjusted for CRP, suggesting that the
TNFRs mirror pathogenic aspects that are independent of
CRP. The models were also adjusted for statins, which have
been shown to reduce the inﬂammation level,29 and to reduce
the risk of adverse events in similar patients as in the present
study.30 We also considered that there may have been an
A B
Figure 2. Spline curve of the association between the soluble receptor for tumor necrosis factor-a 2
(sTNFR2) and the composite outcome as hazard ratio with 95% conﬁdence intervals (dotted lines) in the
discovery cohort (A) and the replication cohort (B). The mean level of sTNFR2 was 53862011 pg/mL in
the discovery cohort and 54162099 pg/mL in the replication cohort.
Table 5. Improvement of Outcome Prediction by Adding TNFR1 and TNFR2, Respectively, to the SP Full Model*
Type of Predictions
TNFR1 TNFR2
SPs Included
SPs Plus
Biomarker
Included
Total
Predictions SPs Included
SPs Plus
Biomarker
Included
Total
Predictions
Composite outcome, n (%)
True favorable predictions 2910 (48.7) 2908 (48.7) 5972 2910 (48.7) 2922 (48.9) 1996
True unfavorable predictions 1174 (19.7) 1176 (19.7) 1174 (19.7) 1185 (19.8) 1989
Total true predictions 4084 (68.4) 4084 (68.4) 4084 (68.4) 4107 (68.8) 1987
5972
All-cause mortality, n (%)
True favorable predictions 4585 (76.8) 4580 (76.7) 5971 4585 (76.8) 4383 (73.4) 1996
True unfavorable predictions 392 (6.57) 403 (6.75) 392 (6.57) 408 (6.83) 1989
Total true predictions 4977 (83.4) 4983 (83.5) 4977 (83.4) 4991 (83.6) 1986
5971
For TNFR1, the increase in the number of true predictions when we use the biomarker plus the SPs instead of using only the SPs for the outcome all-cause mortality. This amounts to
49834977=6. In percentage of the total number of predictions made (5971), this amounts to 6/5971=0.10%. For TNFR2, the increase in the number of true predictions when we use the
biomarker plus the SPs instead of using only the SPs for the outcome all-cause mortality. This amounts to 49914977=14. In percentage of the total number of predictions made (5971),
this amounts to 14/5971=0.23%. For details of this analysis, the reader is referred to data supplement. SP indicates standard predictor; and TNFR1/TNFR2, soluble receptors for tumor
necrosis factor-a 1/2.
*The number of correct predictions of survival at time=3, 6, and 9 years was recorded when the SPs were included in the model and when the SPs plus the biomarker were included in the
model, and the percentage improvement was obtained by including the biomarker calculated.
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effect modiﬁcation of the strengths of the associations,
depending on if the patient had had a myocardial infarction or
angina pectoris before baseline; however, no such interaction
was found.
Third, hyperglycemia and diabetes mellitus are common in
patients with coronary heart disease and have been shown to
affect the levels of oxidative stress.31,32 Oxidative stress
increases the overall TNF-a system activity31 and has been
shown to be associated with TNFR2,33 which showed the
highest risk estimates in the present study. Hyperglycemia
may also cause arterial stiffness. Pulse wave velocity is a
common surrogate for arterial stiffness and has been shown
to be highly correlated with endogenous levels of TNFR1 and
TNFR2 in patients with type 2 diabetes mellitus,34 as well as
in patients with coronary atherosclerosis.35 Another mecha-
nism associated with metabolic disturbances is a procoagu-
lant and hypoﬁbrinolytic state, which is highly prevalent in
patients with coronary heart disease.36 It is thus possible that
the elevated levels of TNFR1 and TNFR2 reﬂect these
metabolic disturbances.
Fourth, the increased risk of AMI and cardiovascular
mortality in patients with coronary heart disease with elevated
TNFR1 and TNFR2 levels could partly be explained by an
association with angiogenesis, as has been shown for TNFR1
in ischemic models.37
Finally, associations between kidney function and TNFR1
and TNFR2 have been shown repeatedly to be strong.3,4,21
Thus, a reduced kidney function appears to be an important
mediator that may explain the link between the TNFRs and
AMI as well as cardiovascular mortality. Moreover, TNFR1 and
TNFR2 predict the progression of chronic kidney disease in
patients with diabetes mellitus.38,39 Therefore, it is possible
that individuals with elevated endogenous TNFR levels are
more likely to be developing chronic kidney disease, which, in
turn, substantially increases the risk of cardiovascular events.
Accordingly, the risk estimates were somewhat attenuated
after adjustment for baseline estimated glomerular ﬁltration
rate, indicating that some of the risk that the receptors
portray is attributable to kidney function.
Comparisons With Other Studies
Higher levels of TNFR1 and TNFR2 have previously been
associated with an increased risk of cardiovascular events
and mortality in speciﬁc patient groups, such as in people with
diabetes mellitus,4,8,10 chronic kidney disease,7,40,41 rheuma-
toid arthritis,6 or heart failure after myocardial infarction,42–44
as well as in the general population.3,9 No association with
mortality risk was found in patients undergoing hemodialysis.45
These previous associations were generally independent of
more established inﬂammatory markers, such as CRP, in
most,3,6,9,10,41,44,45 but not all, studies.7,8 The present study is
unique in that it reports the independent association between
the TNFRs and the 10-year risk of adverse outcomes in
patients with stable coronary heart disease. The long-term
follow-up in the present study resulted in similar risk
estimates as in previous studies. Only one of the previous
studies assessed prediction improvement and found it to be
<1% when CRP and TNFR2 were added to a model with
established risk factors,9 which is in agreement with our
study. In line with previous studies,4,21,45 TNFR1 and TNFR2
were highly correlated to one another (q0.7).
Clinical Implications
Anti-TNF therapies are widely used in clinical practice to
inhibit the inﬂammatory cascades in rheumatic diseases and
have not been associated with increased cardiovascular risk
in these patients.46 Moreover, improvements in the left
ventricular structure have been seen in patients with heart
failure when treated with anti-TNF therapy.47 However, a
mouse model study of myocardial infarction reported both
protective and harmful effects of TNFR1 administration; there
were effects on apoptosis of cells inﬁltrating the heart tissue
and on vascular remodeling of the heart.48
Our data imply that circulating levels of endogenous TNFR1
and TNFR2 identify risk independently of established risk
factors in patients with stable coronary heart disease.
However, the improvement in risk prediction beyond standard
predictors was small. Moreover, it remains to be shown if the
risk associated with circulating levels of TNFR1 and TNFR2
can be lowered by statins, anti-TNF therapy, other pharma-
ceutical drugs, or lifestyle interventions. Thus, our data do not
support the notion of clinical utility of monitoring endogenous
levels of TNFR1 and TNFR2 in high-risk individuals with stable
coronary heart disease.
Conclusion
We have shown that endogenous TNFR1 and TNFR2 are
associated with incident cardiovascular events and mortality,
independently of established risk factors in patients with
stable coronary heart disease. We warrant further studies that
will help us gain a better understanding about TNF-associated
molecules in human disease and to determine a possible
future clinical role of endogenous levels of TNFR1 and TNFR2
to monitor and treat patients at risk of cardiovascular events.
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Table S1. Standard predictors adjusted for in Model D. 
 
Clinical predictors Current medical treatment Standard biochemical predictors 
Sex, age* at entry, smoking history, 
history of myocardial infarction 
compared to angina only, 
hypertension, 
and diabetes. 
 
The current 
medical treatment was included as 
proxy predictors because 
information about post infarction 
heart failure and post-infarction 
angina pectoris are not available to 
us. 
Aspirin (Yes/No), beta-blocker 
(Yes/No), calcium-antagonist 
(Yes/No), ACE-inhibitor (Yes/ 
No), long lasting nitrate (Yes/No), 
diuretic (Yes/No), digoxin (Yes/No), 
statin (Yes/No), and anti-arrhythmic 
drugs (Yes/No).  
 
 
Log transformed high-sensitivity-
reactive protein (CRP), glomerular 
filtration rate (GFR) estimated by 
creatinine, triglycerides and 
lipoproteins (total cholesterol, HDL 
cholesterol, LDL cholesterol, 
apoprotein A1, and 
log(apoprotein B)). 
 
*Age was omitted from Model D for the composite outcome as well as for all-cause death outcome due to violation of 
the proportional hazard assumption. 
 by guest on June 27, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Table S2. Logistic regression analyses for outcomes that violated the proportional hazard assumption for age for the fully 
adjusted model (model D).  
 
  Discovery Replication 
  TNFR1 TNFR2 TNFR1 TNFR2 
Composite 
endpoint 
Odds Ratio 
95% CI 
p-value 
1.22 
1.08 to 1.38 
0.001 
1.22 
1.07 to 1.38 
0.003 
1.23 
1.09 to 1.39 
0.001 
1.22 
1.07 to 1.38 
0.003 
Alltocause 
mortality 
Odds ratio 
95% CI 
p-value 
1.39 
1.21 to 1.58 
<0.001 
1.40 
1.22 to 1.61 
<0.001 
1.32 
1.16 to 1.51 
<0.001 
1.29 
1.12 to 1.47 
<0.001 
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Table S3. Accelerated failure regression analyses for outcomes that violated the proportional hazard assumption for age for 
the fully adjusted model (model D).  
 
  Discovery Replication 
  TNFR1 TNFR2 TNFR1 TNFR2 
Composite 
endpoint 
Coefficient 
95% CI 
p-value 
-0.10 
-0.16, to 0.33 
0.003 
-0.11 
-0.18 to 0.048 
0.001 
-0.14 
-0.20 to 0.075 
<0.001 
-0.13 
-0.20, to 0.059 
<0.001 
Alltocause 
mortality 
Coefficient 
95% CI 
p-value 
-0.16 
-0.22 to 0.10 
<0.001 
-0.18 
-0.24 to 0.12 
<0.001 
-0.15 
-0.21 to 0.084 
<0.001 
-0.14 
-0.20 to 0.069 
<0.001 
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Figure S1. Histogram of sTNFR1 in the discovery and replication sample. 
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Figure S2. Histogram of sTNFR2 in the discovery and replication sample. 
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